DMG Stock Overview
Engages in the production and sale of chemical and cosmetic assortments in Poland and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Dr. Miele Cosmed Group S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł4.59 |
| 52 Week High | zł5.32 |
| 52 Week Low | zł2.73 |
| Beta | 1.83 |
| 1 Month Change | -10.00% |
| 3 Month Change | 3.15% |
| 1 Year Change | 39.09% |
| 3 Year Change | 2.00% |
| 5 Year Change | 270.16% |
| Change since IPO | 149.46% |
Recent News & Updates
Recent updates
Dr. Miele Cosmed Group S.A. (WSE:DMG) Soars 33% But It's A Story Of Risk Vs Reward
Sep 22
Dr. Miele Cosmed Group S.A.'s (WSE:DMG) Subdued P/S Might Signal An Opportunity
Jul 24Global Cosmed S.A.'s (WSE:GLC) 32% Price Boost Is Out Of Tune With Earnings
Mar 05Global Cosmed (WSE:GLC) Might Have The Makings Of A Multi-Bagger
Nov 09Returns On Capital Are Showing Encouraging Signs At Global Cosmed (WSE:GLC)
Jul 25Global Cosmed (WSE:GLC) Shareholders Will Want The ROCE Trajectory To Continue
Jan 05Returns Are Gaining Momentum At Global Cosmed (WSE:GLC)
Jan 05With EPS Growth And More, Global Cosmed (WSE:GLC) Is Interesting
Oct 07Global Cosmed S.A.'s (WSE:GLC) 27% Jump Shows Its Popularity With Investors
Sep 06Is Global Cosmed (WSE:GLC) Using Too Much Debt?
Sep 02Slowing Rates Of Return At Global Cosmed (WSE:GLC) Leave Little Room For Excitement
May 17Global Cosmed (WSE:GLC) Seems To Use Debt Rather Sparingly
Mar 16Introducing Global Cosmed (WSE:GLC), The Stock That Soared 586% In The Last Year
Feb 22Declining Stock and Decent Financials: Is The Market Wrong About Global Cosmed S.A. (WSE:GLC)?
Feb 02
The Trends At Global Cosmed (WSE:GLC) That You Should Know About
Jan 12Do Institutions Own Global Cosmed S.A. (WSE:GLC) Shares?
Dec 21Global Cosmed (WSE:GLC) Could Easily Take On More Debt
Nov 23Shareholder Returns
| DMG | PL Personal Products | PL Market | |
|---|---|---|---|
| 7D | -3.8% | -4.2% | -2.8% |
| 1Y | 39.1% | 10.5% | -4.9% |
Return vs Industry: DMG exceeded the Polish Personal Products industry which returned 10.5% over the past year.
Return vs Market: DMG exceeded the Polish Market which returned -4.9% over the past year.
Price Volatility
| DMG volatility | |
|---|---|
| DMG Average Weekly Movement | 6.4% |
| Personal Products Industry Average Movement | 3.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in PL Market | 8.8% |
| 10% least volatile stocks in PL Market | 3.1% |
Stable Share Price: DMG has not had significant price volatility in the past 3 months compared to the Polish market.
Volatility Over Time: DMG's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1824 | 537 | Magdalena Miele | dr-miele.eu |
Dr. Miele Cosmed Group S.A. engages in the production and sale of chemical and cosmetic assortments in Poland and internationally. The company offers washing and care cosmetics, wet wipes, and laundry detergents for children; cleansing cosmetics, such as sanitizing gels and sprays, and liquid soaps; shower gels; and drain opener granules and gels; washing liquids and fabric softening concentrates; cleaning agents for kitchens and bathrooms; and hand sanitizing and surface disinfectants. It markets its products primarily under the Bobini, Apart, Biophen, Mole, Sofin, Izo, and Izozid brands.
Dr. Miele Cosmed Group S.A. Fundamentals Summary
| DMG fundamental statistics | |
|---|---|
| Market cap | zł400.88m |
| Earnings (TTM) | zł35.95m |
| Revenue (TTM) | zł483.07m |
11.2x
P/E Ratio0.8x
P/S RatioIs DMG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMG income statement (TTM) | |
|---|---|
| Revenue | zł483.07m |
| Cost of Revenue | zł276.01m |
| Gross Profit | zł207.06m |
| Other Expenses | zł171.11m |
| Earnings | zł35.95m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.41 |
| Gross Margin | 42.86% |
| Net Profit Margin | 7.44% |
| Debt/Equity Ratio | 21.8% |
How did DMG perform over the long term?
See historical performance and comparisonDividends
2.0%
Current Dividend Yield22%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 03:53 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dr. Miele Cosmed Group S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|